[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 203,636
  • Shares Outstanding, K 222,019
  • Annual Sales, $ 2,040 K
  • Annual Income, $ -40,830 K
  • EBIT $ -114 M
  • EBITDA $ -107 M
  • 60-Month Beta 2.31
  • Price/Sales 89.91
  • Price/Cash Flow N/A
  • Price/Book 15.76

Options Overview Details

View History
  • Implied Volatility 140.70% (-33.16%)
  • Historical Volatility 120.83%
  • IV Percentile 63%
  • IV Rank 18.80%
  • IV High 366.53% on 03/09/26
  • IV Low 88.42% on 07/03/25
  • Expected Move (DTE 28) 0.2720 (26.54%)
  • Put/Call Vol Ratio 0.59
  • Today's Volume 4,075
  • Volume Avg (30-Day) 1,960
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 91,636
  • Open Int (30-Day) 86,018
  • Expected Range 0.7530 to 1.2970

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.10
  • Number of Estimates 3
  • High Estimate $-0.04
  • Low Estimate $-0.14
  • Prior Year $-0.24
  • Growth Rate Est. (year over year) +58.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6664 +53.81%
on 04/22/26
1.2200 -15.98%
on 05/14/26
+0.3660 (+55.54%)
since 04/21/26
3-Month
0.5469 +87.42%
on 03/30/26
1.3100 -21.76%
on 03/10/26
-0.1050 (-9.29%)
since 02/20/26
52-Week
0.5469 +87.42%
on 03/30/26
2.9300 -65.02%
on 06/06/25
-1.3150 (-56.20%)
since 05/21/25

Most Recent Stories

More News
Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals – - SAC awards require intensive product and value analysis vetting by a surgical committee...

HUMA : 1.0100 (+10.12%)
Humacyte Q1 Earnings Call Highlights

Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its bioengineered...

HUMA : 1.0100 (+10.12%)
Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -  - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million...

HUMA : 1.0100 (+10.12%)
Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

- Distinguished vascular surgeon brings decades of clinical experience, innovation, and leadership to new role at cutting-edge biotech manufacturer - - Appointment brings important surgical experience...

HUMA : 1.0100 (+10.12%)
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC (“KSF”), announces that KSF has commenced an investigation into...

HUMA : 1.0100 (+10.12%)
Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 1.0100 (+10.12%)
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial...

HUMA : 1.0100 (+10.12%)
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

NEW YORK and NEW ORLEANS , April 24, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti , LLC ("KSF"), announces...

HUMA : 1.0100 (+10.12%)
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care -  - Positions Humacyte to advance discussions with corporate partners regarding international and...

HUMA : 1.0100 (+10.12%)
Humacyte Appoints Jim Mercadante as Chief Commercial Officer

– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific...

HUMA : 1.0100 (+10.12%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 1.0609
2nd Resistance Point 0.9954
1st Resistance Point 0.9563
Last Price 1.0100
1st Support Level 0.8517
2nd Support Level 0.7862
3rd Support Level 0.7471

See More

52-Week High 2.9300
Fibonacci 61.8% 2.0197
Fibonacci 50% 1.7385
Fibonacci 38.2% 1.4572
Last Price 1.0100
52-Week Low 0.5469

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.